<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> is caused by germline mismatch repair (MMR) gene mutations </plain></SENT>
<SENT sid="1" pm="."><plain>The PREMM(1,2,6) model predicts the likelihood of a MMR gene mutation based on personal and family <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> history </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To compare strategies using PREMM(1,2,6) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> testing (microsatellite instability (MSI) and/or immunohistochemistry (IHC) staining) to identify mutation carriers </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Data from population-based or clinic-based patients with <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> enrolled through the <z:hpo ids='HP_0003003'>Colon Cancer</z:hpo> Family Registry were analysed </plain></SENT>
<SENT sid="4" pm="."><plain>Evaluation included MSI, IHC and germline mutation analysis for MLH1, MSH2, MSH6 and PMS2 </plain></SENT>
<SENT sid="5" pm="."><plain>Personal and family <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> histories were used to calculate PREMM(1,2,6) predictions </plain></SENT>
<SENT sid="6" pm="."><plain>Discriminative ability to identify carriers from non-carriers using the area under the receiver operating characteristic curve (AUC) was assessed </plain></SENT>
<SENT sid="7" pm="."><plain>Predictions were based on logistic regression models for (1) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> assessment using PREMM(1,2,6), (2) MSI, (3) IHC for loss of any MMR protein expression, (4) MSI+IHC, (5) PREMM(1,2,6)+MSI, (6) PREMM(1,2,6)+IHC, (7) PREMM(1,2,6)+IHC+MSI </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Among 1651 subjects, 239 (14%) had mutations (90 MLH1, 125 MSH2, 24 MSH6) </plain></SENT>
<SENT sid="9" pm="."><plain>PREMM(1,2,6) discriminated well with AUC 0.90 (95% CI 0.88 to 0.92) </plain></SENT>
<SENT sid="10" pm="."><plain>MSI alone, IHC alone, or MSI+IHC each had lower AUCs: 0.77, 0.82 and 0.82, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>The added value of IHC+PREMM(1,2,6) was slightly greater than PREMM(1,2,6)+MSI (AUC 0.94 vs 0.93) </plain></SENT>
<SENT sid="12" pm="."><plain>Adding MSI to PREMM(1,2,6)+IHC did not improve discrimination </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: PREMM(1,2,6) and IHC showed excellent performance in distinguishing mutation carriers from non-carriers and performed best when combined </plain></SENT>
<SENT sid="14" pm="."><plain>MSI may have a greater role in distinguishing <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> from other familial <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> subtypes among cases with high PREMM(1,2,6) scores where genetic evaluation does not disclose a MMR mutation </plain></SENT>
</text></document>